



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/812,636-Conf. #3487		
		Filing Date	March 29, 2004		
		First Named Inventor	Nehal MOHAMED		
		Art Unit	1645		
		Examiner Name	K.S. Shahnan Shah		
Sheet	1	of	3	Attorney Docket Number	ELI-029

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
IKS/	A1*	US-4,474,893	10-02-1984	Reading	
	A2*	US-5,212,071	05-18-1993	Fearon et al.	
	A3*	US-5,470,570	11-28-1995	Taylor et al.	
	A4*	US-5,487,890	01-30-1996	Taylor et al.	
	A5*	US-5,798,229	08-25-1998	Strittmatter et al.	
	A6*	US-5,879,679	03-09-1999	Taylor et al.	
	A7*	US-5,959,084	09-28-1999	Ring et al.	
	A8*	US-6,316,604	11-13-2001	Fearon et al.	
	A9*	US-20020103343-A1	08-01-2002	Taylor et al.	
	A10*	US-6,479,729	11-12-2002	Campochiaro et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
/KS/	B1	WO-92/05801-A1	04-16-1992	University of Virginia Patents Foundation		
	B2	WO-95/22977-A1	08-31-1995	University of Virginia Patents Foundation		
	B3	WO-01/45669-A1	06-28-2001	Elusys Therapeutics, Inc.		
	B4	WO-01/80883-A1	11-01-2001	Elusys Therapeutics, Inc.		
	B5	WO-02/46208-A2	06-13-2002	Elusys Therapeutics, Inc.		
	B6	WO-02/075275-A2	09-26-2002	Elusys Therapeutics, Inc.		
	B7	WO-03/007971-A1	01-30-2003	University of Virginia Patent Foundation		
KS	B8	WO-04/024889-A2	03-25-2004	Elusys Therapeutics, Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
IKS/	C1	Craig, Maria L. et al., "Infusion of Bispecific Monoclonal Antibody Complexes into Monkeys Provides Immunologic Protection against Later Challenge with a Model Pathogen," <i>Clinical Immunology</i> , Vol. 92(2):170-180 (1999)	
IKS/	C2	Edberg, J.C. et al., "Functional characterization of non-human primate erythrocyte immune adherence receptors: implications for the uptake of immune complexes by the cells of the mononuclear phagocytic system," <i>Eur. J. Immunol.</i> , Vol. 22(6):1333-1339 (1992)	

Examiner Signature	/Khatol Shahnan Shah/	Date Considered	06/07/2007
-----------------------	-----------------------	--------------------	------------

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/812,636-Conf. #3487
				Filing Date	March 29, 2004
				First Named Inventor	Nehal MOHAMED
				Art Unit	1645
				Examiner Name	K.S. Shahnan Shah
Sheet	2	of	3	Attorney Docket Number	ELI-029

/KS/	C3	Hahn, Chang S. et al., "Bispecific Monoclonal Antibodies Mediate Binding of Dengue Virus to Erythrocytes in a Monkey Model of Passive Viremia," <i>The Journal of Immunology</i> , Vol. 166:1057-1065 (2001)	
	C4	Henchal, E.A. et al., "Epitopic Analysis of Antigenic Determinants on the Surface of Dengue-2 Virions Using Monoclonal Antibodies," <i>Am. J. Trop. Med. Hyg.</i> , Vol. 34(1):162-169 (1985)	
	C5	Klickstein, Lloyd B. et al., "Identification of Distinct C3b and C4b Recognition Sites in the Human C3b/C4b Receptor (CR1, CD35) by Deletion Mutagenesis," <i>J. Exp. Med.</i> , Vol. 168:1699-1717 (1988)	
	C6	Kuhn, Susan E. et al., "Escherichia coli Bound to the Primate Erythrocyte Complement Receptor via Bispecific Monoclonal Antibodies Are Transferred to and Phagocytosed by Human Monocytes in an In Vitro Model," <i>The Journal of Immunology</i> , Vol. 160:5088-5097 (1998)	
	C7	Lindorfer, Margaret A. et al., "Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications," <i>Immunological Reviews</i> , Vol. 183:10-24 (2001)	
	C8	Little, Stephen F. et al., "Production and Characterization of Monoclonal Antibodies to the Protective Antigen Component of <i>Bacillus anthracis</i> Toxin," <i>Infection and Immunity</i> , Vol. 56(7):1807-1813 (1988)	
	C9	Mabry, Robert et al., "Protection Against Anthrax Toxin by Heteropolymers Directed Against Protective Antigen," <i>Abstracts of Papers American Chemical Society</i> , Vol. 225(1-2):124 (2003)	
	C10	Nardin, A. et al., "A prototype pathogen bound ex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model," <i>Eur. J. Immunol.</i> , Vol. 29(5):1581-1586 (1999)	
	C11	Nardin, A. et al., "How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocyte cells?" <i>Mol. Immunol.</i> , Vol. 36(13-14):827-835 (1999)	
	C12	Nardin, A. et al., "Quantitative studies of heteropolymer-mediated binding of inactivated Marburg virus to the complement receptor on primate erythrocytes," <i>J. Immunol. Methods</i> , Vol. 211(1-2):21-31 (1998)	
	C13	Nickells, M. et al., "Mapping epitopes for 20 monoclonal antibodies to CR1," <i>Clin. Exp. Immunol.</i> , Vol. 112:27-33 (1998)	
	C14	Perez, P. et al., "Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody," <i>Nature</i> , Vol. 316(6026):354-356 (1985)	
	C15	Powers, John H. et al., "Complement-Independent Binding of Microorganisms to Primate Erythrocytes In Vitro by Cross-Linked Monoclonal Antibodies via Complement Receptor 1," <i>Infection and Immunity</i> , Vol. 63(4):1329-1335 (1995)	
	C16	Reilly, Brian D. et al., "Quantitative Analysis of C4b Dimer Binding to Distinct Sites on the C3b/C4b Receptor (CR1)," <i>The Journal of Biological Chemistry</i> , Vol. 269(10):7696-7701 (1994)	
	C17	Reist, C.J. et al., "Antigens pre-bound to the primate erythrocyte complement receptor via cross-linked bispecific monoclonal antibody heteropolymers are rapidly cleared from the circulation," <i>Eur. J. Immunol.</i> , Vol. 23(11):3021-3027 (1993)	
	C18	Roehrig, John T. et al., "Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica," <i>Virology</i> , Vol. 246:317-328 (1998)	
✓	C19	Taylor, Ronald P. et al., "Bispecific Monoclonal Antibody Complexes Bound to Primate Erythrocyte Complement Receptor 1 Facilitate Virus Clearance in a Monkey Model," <i>The Journal of Immunology</i> , Vol. 158:842-850 (1997)	

Examiner Signature	/Khatol Shahnan Shah/	/KS/	Date Considered	06/07/2007
--------------------	-----------------------	------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/812,636-Conf. #3487
				Filing Date	March 29, 2004
				First Named Inventor	Nehal MOHAMED
				Art Unit	1645
				Examiner Name	K.S. Shannan Shah
Sheet	3	of	3	Attorney Docket Number	ELI-029

/KS/	C20	Taylor, Ronald P. et al., "Bispecific Monoclonal Antibody Complexes Facilitate Erythrocyte Binding and Liver Clearance of a Prototype Particulate Pathogen in a Monkey Model," <i>The Journal of Immunotherapy</i> , Vol. 159:4035-4044 (1997)	
	C21	Taylor, Ronald P. et al., "Clearance of blood-borne pathogens mediated through bispecific monoclonal antibodies bound to the primate erythrocyte complement receptor," <i>Cancer Immunol. Immunother.</i> , Vol. 45:152-155 (1997)	
	C22	Taylor, Ronald P. et al., "In Vivo Binding and Clearance of Circulating Antigen by Bispecific Heteropolymer-Mediated Binding to Primate Erythrocyte Complement Receptor," <i>The Journal of Immunology</i> , Vol. 148(8):2462-2468 (1992)	
↓	C23	Taylor, Ronald P. et al., "Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: A potential therapeutic treatment," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 88:3305-3309 (1991)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

/KS/

Examiner Signature	/Khatol Shannan Shah/	Date Considered	06/07/2007
-----------------------	-----------------------	--------------------	------------